 |
Welcome
TVM
Clinical Evidence
How to Buy / Clinical Training
US Reimbursement
Investor Relations
Contact Us
|
|
UK NHSÕs Centre for Evidence-based Purchasing publishes evidence review and economic assessment of oesophageal Doppler monitoring 15 April 2008 Deltex Medical Group plc ("Deltex Medical"), the UK's leading haemodynamic monitoring company, today announces the results of a new report on the CardioQ™ technology of Oesophageal Doppler Monitoring (ODM). The report is an Evidence Review by the Centre for Evidence-based Purchasing (CEP), which is part of the Policy and Innovation Directorate of the NHS Purchasing and Supply Agency. The report is "based on evidence contained in a high-quality 2007 systematic review of ODM in patients during surgery and post-operatively from the US Agency for Healthcare Research and Quality (AHRQ)": the Company notes that this is the same AHRQ review which drove the decision of the Centres for Medicare and Medicaid Services to cover ODM for reimbursement nationally across the USA. In respect of use during surgery, the Company's key target market for the CardioQ™, the CEP report concludes: "In patients undergoing high-risk surgery, addition of ODM-guided fluid administration to CVP monitoring plus conventional clinical assessment (comparison 1) is likely to result in fewer deaths, fewer complications, and a shorter length of hospital stay. The costs of ODM are likely to be offset by reductions in both complications and length of hospital stay (although the costs of treatments prompted by monitoring are uncertain)". The economic analysis associated with this conclusion calculates a range of per patient equipment costs of between £65.60 per patient and £214.15 per patient (dependent on probe variant and frequency of use of the monitor). It also calculated a range of savings per patient from using the CardioQ™ of between £642 and £4,441. Comparing the highest cost above with the lowest saving indicates that the NHS saves at least £3.00 for every £1.00 it spends on the CardioQ™: the saving rises to £67.00 for every £1.00 spent on the CardioQ™ if the lowest cost per patient is compared to the highest benefit. CEP gives one of four verdicts to health technologies based on its evidence reviews ranging from "recommended" to "not recommended". In respect of ODM its verdict is "significant potential", although the Company notes that CEP has never given any technology a higher verdict than "significant potential". The CEP report provides an early synopsis of a technology assessment report commissioned by the National Coordinating Centre for Health Technology Assessment and which is due to be published in October 2008. The CEP report is available at www.pasa.nhs.uk/PASAWeb/NHSprocurement/CEP. Deltex Medical's Chief Executive, Andy Hill commented: "The CEP report confirms once again the strong evidence that the CardioQ™ significantly improves outcomes for large numbers of patients undergoing surgery. This is the first UK Government commissioned economic analysis of the potential impact of the CardioQ™ across the NHS and the results are stunning, with savings identified of up £4,441 per patient. This report will make it harder than ever before for the NHS to deny funding to those clinicians wishing to use the CardioQ™. "We will be seeking to work closely with the report's authors over the coming months to provide them with whatever extra information they feel they need in order to recommend the CardioQ™ be formally recognised as a standard of care for a significant proportion of the 3,000,000 NHS patients who undergo surgery every year." For further information, please contact: Deltex Medical Group plc 01243 774 837 Gavin Anderson & Company 020 7554 1400 Charles Stanley Securities 020 7149 6000
|